Have you or your loved ones been diagnosed with hematologic malignancies?

You may be eligible to participate in a hematologic malignancies clinical trial.

Have you or your loved ones been diagnosed with hematologic malignancies? You may be eligible to participate in a hematologic malignancies clinical trial.

What is a clinical trial? Is participating in a clinical trial right for you? Learn more

Hematologic Malignancies Clinical Trial
NCT03082209 | Phase 1 | Interventional
AbbVie
Sponsored by
AbbVie

Have you or your loved ones been diagnosed with hematologic malignancies?

You may be eligible to participate in a hematologic malignancies clinical trial.

Have you or your loved ones been diagnosed with hematologic malignancies? You may be eligible to participate in a hematologic malignancies clinical trial.

Completed

Male & Female

18 Years +

This study has recruited 153 Participants

This is an open-label, Phase I, dose-escalation study to determine the maximum tolerated dose (MTD) and/or recommended phase two dose (RPTD), and evaluate the safety, efficacy, and pharmacokinetic (PK) profile of ABBV-621 for participants with previously-treated solid tumors or hematologic malignancies. Only chemotherapy combination (ABBV-621 + FOLFIRI) enrolling participants with RAS-mutant CRC who have received one prior line of therapy is open for enrollment.